India · Delayed Price · Currency is INR Cipla Earnings Call Transcripts
Fiscal Year 2026
-
Q3 FY26 revenue was flat YoY at INR 7,074 crore, with India business up 10% and U.S. sales impacted by lower Lenalidomide and lanreotide. EBITDA margin dropped to 17.7% due to product mix and higher R&D, while new launches and strategic deals are expected to drive future growth.
-
Achieved record quarterly revenue and strong EBITDA margin, driven by growth across India, U.S., Africa, and EMEU. Revised full-year EBITDA margin guidance downward due to higher R&D spend and lower Revlimid contribution, while launching new products and entering obesity care with tirzepatide.
-
Q1 FY26 revenue grew 4% YoY to INR 6,957 crore with a 25.6% EBITDA margin and strong cash position. New launches in the US and India, expansion in biosimilars, and a robust pipeline are set to drive future growth despite price erosion and market headwinds.
Fiscal Year 2025
-
Q4 FY25 saw 9% YoY revenue growth and record annual results, with strong performance across India, North America, Africa, and EMU. EBITDA margin exceeded guidance, and the outlook remains positive despite margin headwinds from generic Revlimid.
-
Quarterly revenue hit a record INR 7,073 crore, with 8% YoY growth and EBITDA margin at 28%. US supply issues are being resolved, while key launches like Advair and Abraxane are expected in H2 FY26. Strong cash position supports ongoing investments and acquisitions.
-
Quarterly revenue grew 9% YoY to INR 7,051 crore, with record EBITDA margin of 26.7%. North America faced temporary lanreotide supply issues, while India chronic therapies and Africa segments outperformed. Margin guidance for FY25 remains at 24.5%-25.5%.
-
Branded prescription and North America businesses drove 7% revenue growth and record margins, with strong cash generation and robust launches in peptides. Regulatory and supply risks remain, but guidance for EBITDA margin and R&D spend is maintained.